🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

INmune Bio Inc. INMB R2K

Healthcare · Biotechnology · United States
https://www.inmunebio.com

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

READ MORE ›
$1.41
-80.89% 1Y

Market & Price

Market Cap
$37.49M
Current Price
$1.41
High / Low (52W)
$8.09 / $1.12
Beta
1.05

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.74
Price to Book
1.91
P/S
inf
EV/EBITDA
-
Dividend Yield
-

Profitability & Returns

ROCE
-128.97%
ROE
-
ROA
-52.61%
Profit Margin
0.00%
Op Margin
0.00%
EPS (Latest Qtr)
$-0.20
EPS (TTM)
$-1.63

Balance Sheet & Liquidity

Debt/Equity
0.08
Quick Ratio
4.11
Current Ratio
4.24
Debt
$1.51M
Total Assets
$32.35M
Current Assets
$29.89M
Working Capital
$21.47M

Ownership

Promoter Holding
11.16%
Chg in Prom Hold
-
FII / Inst Holding
19.70%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$17.64M
Total Revenue (TTM)
$0
EBITDA
-
Free Cash Flow
$-11.25M
Operating Cash Flow
$-19.16M
Shares Outstanding
26.59M
Gross Margin
0.00%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
-48.87%
Profit 5Y
-22.75%
Revenue (YoY)
-
Earnings (YoY)
-

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -48.9% CAGR over 5 years.
  • Earnings shrank at -22.8% CAGR over 5 years.
  • Trading 82.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 INMB INmune Bio Inc. R2K 1.41 - $37.49M - -128.97% - -48.87% -22.75%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
⚙Ad space

Quarterly Results

Figures in USD.

Metric Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 00-00----4.00K-14.00K163.00K16.00K98.00K38.00K46.00K43.00K14.00K--50.00K0000
Cost of Revenue --------------------------
Gross Profit --------------------------
Operating Expenses ---------------------9.96M8.06M7.43M5.47M5.81M
Operating Income -2.85M-6.17M-1.54M-1.91M-428.42K-3.08M-2.09M-2.11M-4.82M-4.55M-6.55M-9.02M-6.48M-6.39M-7.44M-6.42M-6.41M-8.53M-11.02M-9.87M--9.90M-8.06M-7.43M-5.47M-5.81M
EBITDA ----------------------9.90M-8.06M-7.43M-5.42M-5.76M
Interest Expense --------------------------
Pretax Income ----------------------9.74M-24.46M-6.47M-5.26M-5.41M
Tax Provision --------------------------
Net Income -2.85M-6.17M-1.54M-1.90M-392.08K-3.07M-2.07M-2.11M-4.72M-4.56M-6.66M-9.46M-6.90M-6.84M-7.72M-6.54M-6.50M-8.56M-11.03M-9.75M--9.74M-24.46M-6.47M-5.26M-5.41M
Diluted EPS ------------0.55-0.39-0.38-0.43-0.36-0.36-0.48-0.61-0.50-0.60-0.43-1.05-0.24--0.20
R&D Expense 104.01K287.32K654.69K612.71K634.70K1.17M793.00K903.00K2.36M2.49M4.46M6.52M4.31M4.19M5.16M4.13M4.15M5.99M8.69M7.05M10.07M7.64M5.80M4.89M-3.64M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 00-11.00K-374.00K155.00K14.00K50.00K
Cost of Revenue ---------
Gross Profit ---------
Operating Expenses -----26.32M29.90M42.65M30.92M
Operating Income -981.48K-12.44M-7.76M-12.23M--25.95M-29.74M-42.63M-30.87M
EBITDA ------25.95M-29.74M-42.63M-30.79M
Interest Expense ---------
Pretax Income ------27.30M-30.01M-42.08M-45.93M
Tax Provision ---------
Net Income -831.49K-12.44M-7.68M-12.10M--27.30M-30.01M-42.08M-45.93M
Diluted EPS -----1.88-1.52-1.67-2.11-
R&D Expense 435.36K3.35M3.28M5.92M20.54M17.07M20.27M33.17M20.66M

Compounded Sales Growth

5 Years:-48.87%
1 Year:-

Compounded Profit Growth

5 Years:-22.75%
1 Year:-

Stock Price Performance

1 Year:-80.89%
6 Months:-7.24%
3 Months:+9.30%
1 Month:+6.02%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -18.41M17.36M24.47M40.66M-81.80M57.00M39.56M32.35M
Current Assets ------64.67M39.94M22.66M29.89M
Cash & Equivalents 141.66K1.37M186.20K7.00M21.97M-52.15M35.85M20.92M24.75M
Inventory ----------
Receivables ------8.46M2.44M1.41M4.54M
Total Liabilities -309.72K823.77K860.54K1.90M-21.69M18.86M7.46M8.83M
Current Liabilities --823.77K700.38K1.78M-10.92M18.46M7.22M8.42M
Long Term Debt -----14.46M9.70M---
Total Debt ------15.31M10.44M384.00K1.03M
Total Equity -149.20K18.10M16.54M23.61M38.75M-60.10M38.14M32.10M23.52M
Shares Outstanding ------17.95M17.95M22.28M26.59M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -761.83K-2.06M-5.38M-8.94M--22.69M-11.98M-33.36M-22.58M
Investing Cash Flow -100.00K----15.00M0-0-1.04M
Financing Cash Flow 2.06M900.00K12.21M23.89M-729.00K-4.22M18.21M27.61M
Capital Expenditure -----15.00M----1.04M
Free Cash Flow ------22.69M-11.98M-33.36M-23.62M
Net Change in Cash ------21.96M-16.20M-15.15M3.99M

Ratios (Annual)

Figures in %.

Metric Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------
Operating Margin % ----111,163.6%--6,938.8%-19,187.7%-304,535.7%-61,738.0%
Net Margin % ----109,990.9%--7,299.2%-19,360.0%-300,585.7%-91,866.0%
ROE % -4.6%-75.2%-32.5%-31.2%--45.4%-78.7%-131.1%-195.3%
ROCE % --75.2%-32.6%-31.5%--36.6%-77.2%-131.8%-129.0%

Shareholding Pattern

Insiders
11.16%
Institutions
19.70%
Public Float
22.18%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 4.49% 1.19M $1.68M
2 Vanguard Capital Management LLC 2.58% 687.01K $968.69K
3 Geode Capital Management, LLC 1.86% 494.97K $697.91K
4 State Street Corporation 1.09% 290.88K $410.14K
5 AQR Capital Management, LLC 1.02% 270.32K $381.15K
6 UBS Group AG 0.95% 253.34K $357.21K
7 Goldman Sachs Group Inc 0.87% 231.59K $326.54K
8 Raymond James Financial, Inc. 0.76% 203.25K $286.57K
9 Susquehanna International Group, LLP 0.73% 194.39K $274.09K
10 Northern Trust Corporation 0.69% 184.22K $259.76K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for INMB

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space